Brief: Avenue Therapeutics Receives Interim Response To Its Formal Dispute Resolution Request From U.S. FDA Office Of New Drugs
25/10/2021 12:40
Oct 25 (Reuters) - Avenue Therapeutics Inc ATXI.O :
* AVENUE THERAPEUTICS RECEIVES INTERIM RESPONSE TO ITS
FORMAL
DISPUTE RESOLUTION REQUEST FROM U.S. FOOD AND DRUG
ADMINISTRATION OFFICE OF NEW DRUGS
Source text for Eikon: ID:nGNX14xY3d
Further company coverage: ATXI.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Avenue Therapeutics
See all newsBrief: Axsome Therapeutics Acquires AZD7325, A Selective GABA-A Modulator For Treatment Of Epilepsy
Avenue Therapeutics Inc expected to post a loss of 57 cents a share - Earnings Preview
Brief: Avenue Therapeutics Annji Intends To Terminate License Agreement With Co
Brief: Avenue Therapeutics Receives Delist Letter From Nasdaq Under Nasdaq Listing Rule 5550(B)(1)
Avenue Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary